iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Entero Healthcare Shares Dip on Debut; Lists at ₹1228 on NSE

16 Feb 2024 , 09:52 AM

Entero Healthcare Solutions, a distributor of healthcare products, faced a muted listing as its shares debuted at a discount of 2% on both the NSE and BSE. The shares were listed at ₹1228.70 on the NSE, reflecting a 2.33% decline from the issue price of ₹1258, while they opened at ₹1245 on the BSE, indicating a 1.03% discount.

Experts attribute the lackluster listing to several factors, including the tepid response to the initial public offering (IPO) and weak earnings performance in previous financial years. Despite turning profitable in the six-month period ending September FY24, the company's historical performance, particularly in FY23, remained a concern for investors.

The ₹1,600-Crore public issue garnered tepid interest, with a subscription of just 1.53 times during the period from February 9 to 13, marking the lowest subscription numbers since the HMA Agro Industries IPO in June 2023. Qualified institutional buyers supported the issue, subscribing 2.28 times the allotted quota, while retail investors subscribed 1.33 times. However, non-institutional investors, particularly high net worth individuals, displayed less enthusiasm, subscribing to only 22% of the reserved portion.

Despite these challenges, Entero Healthcare Solutions demonstrated positive momentum in its financial performance. In the six months ended September FY24, the company achieved a net profit of ₹11.64 Crore, compared to a loss of ₹10.86 Crore in the corresponding period of the previous fiscal year. This turnaround was supported by robust operating numbers, with revenue from operations increasing by 19.7% to ₹1,895.5 Crore during the same period.

In FY23, the company posted a narrower loss of ₹11.1 Crore, down from ₹29.4 Crore in the previous fiscal year, while revenue from operations grew by 30.85% to ₹3,300 Crore. In FY21, the company reported a loss of ₹15.35 Crore on revenue of ₹1,779.7 Crore.

Related Tags

  • Entero Healthcare
  • Entero Healthcare IPO
  • Entero Healthcare IPO listing price
  • Entero Healthcare IPO price
  • Entero Healthcare IPO share price
  • Entero Healthcare listing
  • Entero Healthcare share price
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

closeIcon

Get better recommendations & make better investments

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp